Trial ID or NCT#





This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that tumors need to grow. It is not yet known whether giving paclitaxel with combination chemotherapy once every three weeks is more effective than giving paclitaxel once a week in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.

Official Title

A Randomized Phase III Trial of Dose Dense Weekly Paclitaxel Combined With Carboplatin Versus Dose Dense Weekly Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921), Combined With Carboplatin Versus Every-3-Weeks Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921) Combined With Carboplatin in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No


Jonathan S. Berek, MD, MMS
Gynecologic oncologist
Laurie Kraus Lacob Professor
Nelson Teng, MD, PhD
Gynecologic oncologist, Medical oncologist, Obstetrician/gynecologist
Professor of Obstetrics and Gynecology (Oncology)

Contact us to find out if this trial is right for you.


Cancer Clinical Trials Office
(650) 498-7061